文章：

翻译癌前生物学加速非小细胞肺癌的拦截

Translating premalignant biology to accelerate non-small-cell lung cancer interception

原文发布日期：2025-02-24

DOI: 10.1038/s41568-025-00791-1

类型: Review Article

开放获取: 否

英文摘要：

Over the past decade, substantial progress has been made in the development of targeted and immune-based therapies for patients with advanced non-small-cell lung cancer. To further improve outcomes for patients with lung cancer, identifying and intercepting disease at the earliest and most curable stages are crucial next steps. With the recent implementation of low-dose computed tomography scan screening in populations at high risk, there is an emerging unmet need for new diagnostic, prognostic and therapeutic tools to help treat patients suspected of harbouring premalignant lesions and minimally invasive non-small-cell lung cancer. Continued advances in the identification of the earliest drivers of lung carcinogenesis are poised to address these unmet needs. Employing multimodal approaches to chart the temporal and spatial maps of the molecular events driving lung premalignant lesion progression will refine our understanding of early carcinogenesis. Elucidating the molecular drivers of premalignancy is critical to the development of biomarkers to detect those incubating a premalignant lesion, to stratify risk for progression to invasive cancer and to identify novel therapeutic targets to intercept that process. In this Review, we summarize emerging insights into the earliest cellular and molecular events associated with lung squamous and adenocarcinoma carcinogenesis and highlight the growing opportunity for translating these insights into clinical tools for early detection and disease interception to transform the outcomes for those at risk for lung cancer.

摘要翻译： 

过去十年间，晚期非小细胞肺癌的靶向治疗和免疫治疗取得了重大进展。为进一步改善肺癌患者预后，在最早可治愈阶段识别并阻断疾病成为关键步骤。随着低剂量计算机断层扫描在高危人群中的推广应用，针对疑似癌前病变及微浸润性非小细胞肺癌患者的新型诊断、预后评估和治疗工具的需求日益凸显。肺癌发生最早驱动因素的持续研究进展有望满足这些未竟需求。采用多模态方法绘制肺癌前病变进展分子事件的时空图谱，将深化我们对早期癌变机制的理解。阐明癌前病变的分子驱动机制对于开发新型生物标志物至关重要——这些标志物既能检测潜伏期癌前病变，又能对进展为浸润性癌的风险进行分层，还可为阻断该进程识别新型治疗靶点。本综述总结了肺鳞癌和肺腺癌相关最早细胞分子事件的新见解，并重点探讨了将这些认知转化为早期检测和疾病阻断临床工具的广阔前景，从而有望彻底改变肺癌高危人群的临床结局。

原文链接：

Translating premalignant biology to accelerate non-small-cell lung cancer interception